4//SEC Filing
MacFarlane Katie 4
Accession 0001573202-17-000013
CIK 0000849636other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 7:54 PM ET
Size
13.5 KB
Accession
0001573202-17-000013
Insider Transaction Report
Form 4
MacFarlane Katie
Director
Transactions
- Other
Common Stock Options (to purchase shares of Common Stock)
2017-12-09+38,114→ 38,114 totalExercise: $1.45Exp: 2022-12-09→ Common Stock (38,114 underlying)
Holdings
- 25,000
Common Stock Options (to purchase shares of Common Stock)
Exercise: $2.00Exp: 2022-06-30→ Common Stock (25,000 underlying) - 25,000
Common Stock Options (to purchase shares of Common Stock)
Exercise: $3.90Exp: 2022-01-18→ Common Stock (25,000 underlying) - 30,770
Common Stock Options (to purchase shares of Common Stock)
Exercise: $7.38Exp: 2021-03-31→ Common Stock (30,770 underlying) - 6,154
Common Stock Options (to purchase shares of Common Stock)
Exercise: $8.13Exp: 2022-06-30→ Common Stock (6,154 underlying) - 9,231
Common Stock Options (to purchase shares of Common Stock)
Exercise: $6.40Exp: 2022-08-18→ Common Stock (9,231 underlying)
Footnotes (7)
- [F1]On December 9, 2017, Ms. MacFarlane forgave all of the accrued but unpaid directors fees to which she was entitled as of September 30, 2017, an aggregate of $55,000. On that date, the Company granted to Ms. MacFarlane options to purchase 38,114 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $55,000. These Common Stock Options vested upon issuance.
- [F2]These Common Stock Options vested upon issuance.
- [F3]These Common Stock Options vested in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017, and are all currently vested.
- [F4]The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
- [F5]These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested.
- [F6]These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested.
- [F7]The Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested.
Documents
Issuer
RespireRx Pharmaceuticals Inc.
CIK 0000849636
Entity typeother
Related Parties
1- filerCIK 0001608535
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 7:54 PM ET
- Size
- 13.5 KB